Pα+ Psychedelic Patent Analysis: March 2024 – Psychedelic Alpha

General Overview
First Look at Nolan Williams et al.’s Ibogaine IP: Is Co-Administration of Magnesium and Ibogaine Common Practice?
Clexio Biosciences Protects CLE-100 Development Programs
Broad Strokes Attempt from Axsome Fails to Overcome Prior Art
NYU Abandons “Hot Psilocybin Patent Garbage”

***

Each month, we provide an interactive database of psychedelic patents that were granted, allowed, abandoned, rejected or that had responses filed.

We then provide detail and analysis on a handful of specific cases, or one deep dive.

Our monthly Psychedelic Patent Analysis is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.

Companies, organisations and candidates mentioned in this analysis: DemeRx, Axsome Therapeutics, Empyrean Neuroscience, Tactogen, Clexio Biosciences, CLE-100, Gilgamesh Pharmaceuticals, MindMed, Awakn Life Sciences, and others.

Sociodemographic Factors May Predict Substance Use Initiation in Kids

NEW YORK CITY — Sociodemographic factors such as religion and race were the most robust predictors of substance use initiation in early adolescence, according to

May 8, 2024

Cardiac psychologists are pushing to protect heart patients’ often-overlooked mental health

Margery Quackenbush was attending a board meeting of the nonprofit where she served as executive director when she felt a sharp, stabbing pain in her

January 3, 2024

Washington kicks into gear on H5N1

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in

April 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.